Angela B Smith1, Cleo A Samuel2, Sean D McCabe3, Allison Deal4, Mattias Jonsson5, Dana E Mueller6, Zahra M Mahbooba4, Antonia V Bennett7, Arlene E Chung8, Matthew E Nielsen9, Hung-Jui Tan6, Eric Wallen6, Raj Pruthi10, Andrew Wang6, Ethan Basch11, Bryce B Reeve12, Ronald C Chen13. 1. University of North Carolina, Department of Urology, Chapel Hill, NC; University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill, NC. Electronic address: angela_smith@med.unc.edu. 2. University of North Carolina, Department of Urology, Chapel Hill, NC; University of North Carolina, Department of Health Policy and Management, Chapel Hill, NC. 3. University of North Carolina, Lineberger Comprehensive Cancer Center, Biostatistics Core, Chapel Hill, NC; University of North Carolina, Department of Biostatistics, Chapel Hill, NC. 4. University of North Carolina, Lineberger Comprehensive Cancer Center, Biostatistics Core, Chapel Hill, NC. 5. University of North Carolina, Department of Biostatistics, Chapel Hill, NC. 6. University of North Carolina, Department of Urology, Chapel Hill, NC; University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill, NC. 7. University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill, NC; University of North Carolina, Department of Health Policy and Management, Chapel Hill, NC. 8. University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill, NC; University of North Carolina at Chapel Hill School of Medicine, Departments of Medicine and Pediatrics, Chapel Hill, NC. 9. University of North Carolina, Department of Urology, Chapel Hill, NC; University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill, NC; University of North Carolina, Department of Health Policy and Management, Chapel Hill, NC; University of North Carolina, Department of Health Policy and Management, Chapel Hill, NC; Kaiser Permanente Center for Health Research, Portland, OR. 10. University of California- San Francisco, San Francisco, CA. 11. University of North Carolina, Department of Urology, Chapel Hill, NC; University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill, NC; University of North Carolina at Chapel Hill School of Medicine, Department of Medicine, Division of Hematology/Oncology, Chapel Hill, NC. 12. Duke University School of Medicine, Department of Population Health Sciences, Durham, NC. 13. University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill, NC; University of North Carolina, Lineberger Comprehensive Cancer Center, Biostatistics Core, Chapel Hill, NC; University of Kansas, Department of Radiation Oncology, Kansas City, KS.
Abstract
OBJECTIVE: To assess the feasibility of enrollment and collecting patient-reported outcome (PRO) data as part of routine clinical urologic care for bladder and prostate cancer patients and examine overall patterns and racial variations in PRO use and symptom reports over time. SUBJECTS/PATIENTS AND METHODS: We recruited 76 patients (n = 29 Black and n = 47 White) with prostate or bladder cancer at a single, comprehensive cancer center. The majority of prostate cancer patients had intermediate risk (57%) disease and underwent either radiation or prostatectomy. Over half (58%) of bladder cancer patients had muscle invasive disease and underwent cystectomy. Patients were asked to complete PRO symptom surveys using their preferred mode [web- or phone-based interactive voice response (IVR)]. Symptom summary reports were shared with providers during visits. Surveys were completed at 3 time points and assessed urinary, sexual, gastrointestinal, anxiety/depression, and sleep symptoms. Feasibility of enrollment and survey completion were calculated, and linear mixed effects models estimated differences in outcomes by race and time. RESULTS: Sixty three percent of study participants completed all PRO measures at all 3 time points. Black patients were more likely to select IVR as their survey mode (40% vs. 13%, P < 0.05), and less likely to complete all surveys (55% vs. 74%, P = 0.13). Patients using IVR were also less likely to complete all surveys (41% vs. 69%, P = 0.046). CONCLUSIONS: Reported preferences for survey mode and completion rates differ by race, which may influence survey completion rates and highlight potential obstacles for equitable implementation of PROs into clinical care.
OBJECTIVE: To assess the feasibility of enrollment and collecting patient-reported outcome (PRO) data as part of routine clinical urologic care for bladder and prostate cancer patients and examine overall patterns and racial variations in PRO use and symptom reports over time. SUBJECTS/PATIENTS AND METHODS: We recruited 76 patients (n = 29 Black and n = 47 White) with prostate or bladder cancer at a single, comprehensive cancer center. The majority of prostate cancer patients had intermediate risk (57%) disease and underwent either radiation or prostatectomy. Over half (58%) of bladder cancer patients had muscle invasive disease and underwent cystectomy. Patients were asked to complete PRO symptom surveys using their preferred mode [web- or phone-based interactive voice response (IVR)]. Symptom summary reports were shared with providers during visits. Surveys were completed at 3 time points and assessed urinary, sexual, gastrointestinal, anxiety/depression, and sleep symptoms. Feasibility of enrollment and survey completion were calculated, and linear mixed effects models estimated differences in outcomes by race and time. RESULTS: Sixty three percent of study participants completed all PRO measures at all 3 time points. Black patients were more likely to select IVR as their survey mode (40% vs. 13%, P < 0.05), and less likely to complete all surveys (55% vs. 74%, P = 0.13). Patients using IVR were also less likely to complete all surveys (41% vs. 69%, P = 0.046). CONCLUSIONS: Reported preferences for survey mode and completion rates differ by race, which may influence survey completion rates and highlight potential obstacles for equitable implementation of PROs into clinical care.
Authors: Ethan Basch; Allison M Deal; Amylou C Dueck; Howard I Scher; Mark G Kris; Clifford Hudis; Deborah Schrag Journal: JAMA Date: 2017-07-11 Impact factor: 56.272
Authors: David Cella; William Riley; Arthur Stone; Nan Rothrock; Bryce Reeve; Susan Yount; Dagmar Amtmann; Rita Bode; Daniel Buysse; Seung Choi; Karon Cook; Robert Devellis; Darren DeWalt; James F Fries; Richard Gershon; Elizabeth A Hahn; Jin-Shei Lai; Paul Pilkonis; Dennis Revicki; Matthias Rose; Kevin Weinfurt; Ron Hays Journal: J Clin Epidemiol Date: 2010-08-04 Impact factor: 6.437
Authors: James D Slover; Raj J Karia; Chelsie Hauer; Zachary Gelber; Philip A Band; Jove Graham Journal: Am J Manag Care Date: 2015-08 Impact factor: 2.229
Authors: Chantal Quinten; John Maringwa; Carolyn C Gotay; Francesca Martinelli; Corneel Coens; Bryce B Reeve; Henning Flechtner; Eva Greimel; Madeleine King; David Osoba; Charles Cleeland; Jolie Ringash; Joseph Schmucker-Von Koch; Martin J B Taphoorn; Joachim Weis; Andrew Bottomley Journal: J Natl Cancer Inst Date: 2011-12-07 Impact factor: 13.506
Authors: Ethan Basch; Xiaoyu Jia; Glenn Heller; Allison Barz; Laura Sit; Michael Fruscione; Mark Appawu; Alexia Iasonos; Thomas Atkinson; Shari Goldfarb; Ann Culkin; Mark G Kris; Deborah Schrag Journal: J Natl Cancer Inst Date: 2009-11-17 Impact factor: 13.506
Authors: Aaron D Falchook; Rebecca Green; Mary E Knowles; Robert J Amdur; William Mendenhall; David N Hayes; Juneko E Grilley-Olson; Jared Weiss; Bryce B Reeve; Sandra A Mitchell; Ethan M Basch; Bhishamjit S Chera Journal: JAMA Otolaryngol Head Neck Surg Date: 2016-06-01 Impact factor: 6.223
Authors: Scott M Gilbert; David P Wood; Rodney L Dunn; Alon Z Weizer; Cheryl T Lee; James E Montie; John T Wei Journal: Cancer Date: 2007-05-01 Impact factor: 6.860
Authors: Ethan Basch; Allison M Deal; Mark G Kris; Howard I Scher; Clifford A Hudis; Paul Sabbatini; Lauren Rogak; Antonia V Bennett; Amylou C Dueck; Thomas M Atkinson; Joanne F Chou; Dorothy Dulko; Laura Sit; Allison Barz; Paul Novotny; Michael Fruscione; Jeff A Sloan; Deborah Schrag Journal: J Clin Oncol Date: 2015-12-07 Impact factor: 44.544
Authors: Anne M Walling; Jane C Weeks; Katherine L Kahn; Diana Tisnado; Nancy L Keating; Sydney M Dy; Neeraj K Arora; Jennifer W Mack; Philip M Pantoja; Jennifer L Malin Journal: J Pain Symptom Manage Date: 2014-06-26 Impact factor: 3.612
Authors: Elizabeth J Polter; Nidhi Kohli; B R Simon Rosser; Kristine M C Talley; Christopher W Wheldon; Chris J Hoefer; Morgan Wright; Ryan Haggart; Darry Mitteldorf; Gudrun Kilian; Badrinath R Konety; Michael W Ross; William West Journal: J Sex Med Date: 2022-02-04 Impact factor: 3.802